| Autor: |
Akpabio AA; Internal Medicine Department, University of Uyo Teaching Hospital, Uyo. petersakpabio@yahoo.com., Otike-Odibi BI; Internal Medicine Department, University of Port Harcourt Teaching Hospital, Port-Harcourt, Rivers State. bolajio_o@yahoo.com. |
| Jazyk: |
angličtina |
| Zdroj: |
Reumatismo [Reumatismo] 2020 Jul 23; Vol. 72 (2), pp. 115-119. Date of Electronic Publication: 2020 Jul 23. |
| DOI: |
10.4081/reumatismo.2020.1274 |
| Abstrakt: |
Bullous systemic lupus erythematosus (BSLE) is a blistering skin condition occurring in lupus patients. Although cutaneous manifestations are common in lupus (59-85%), BSLE is rare, affecting <5% of lupus patients with very few reported cases among Africans. Dapsone is effective in mild to moderate cases, but off-label standard-dose rituximab (1,000 mg 2 weeks apart) has led to good outcomes in refractory cases. We report the case of a 39-yearold African lady with BSLE, who was successfully treated with low-dose rituximab (500 mg 2 weeks apart), healing her skin lesions at one year post-treatment. Low-dose rituximab may be as effective as standard dosing for the treatment of severe bullous SLE and is recommended in low resource settings. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
